MIC
RCKT icon

Meridian Investment Counsel’s Rocket Pharmaceuticals RCKT Stock Holding History

Meridian Investment Counsel’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,500
Closed -$26K – 190
2017
Q4 		$26K Hold
2,500
– – 0.01% 190
2017
Q3 		$18K Hold
2,500
– – 0.01% 185
2017
Q2 		$19K Hold
2,500
– – 0.01% 181
2017
Q1 		$20K Buy
+2,500
New +$16.8K 0.01% 183

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Meridian Investment Counsel's RCKT Position: Q1 2018 in Review

Meridian Investment Counsel sold out of Rocket Pharmaceuticals (RCKT) in Q1 2018, closing a stake of 2,500 shares — an estimated $26K sold.

Meridian Investment Counsel first reported a position in RCKT in Q1 2017 and held it in 4 quarters. The position peaked at $26K in Q4 2017. 56 funds tracked by Wall St. Rank hold RCKT as of Q1 2018.

  • Meridian Investment Counsel reported no remaining Rocket Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Meridian Investment Counsel sold 2,500 Rocket Pharmaceuticals shares in Q1 2018, an estimated $26K.
  • Meridian Investment Counsel first reported a position in Rocket Pharmaceuticals in Q1 2017 and held it in 4 quarters.
  • Meridian Investment Counsel's Rocket Pharmaceuticals position peaked at $26K in Q4 2017.
  • 56 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2018.

Based on Meridian Investment Counsel's 13F filing for Q1 2018, filed 14 May 2018.